Investigators evaluated the diagnostic accuracy of certain mucosal predictors of Helicobacter pylori status and aimed to validate a simple prediction model.
Investigators assessed the frequency and severity of adverse events associated with H pylori treatments in clinical practice.
The applications are based on data from the phase 3 PHALCON-HP trial.
Investigators conducted a study to determine the relationship between gut microbiota and ghrelin concentrations among patients with positive Helicobacter pylori infection vs those with antigen-negative H pylori infection who received eradication therapy.
Investigators assessed the link between antibiotic consumption and resistance and H pylori infections in European countries.
Researchers performed a network meta-analysis to compare the effectiveness of first-line regimens vs standard triple therapy in the treatment of H pylori infection.
Researchers compared the efficacy, adverse events, and compliance of HDDT vs BQT as first-line or rescue regimens and investigated factors contributing to H pylori eradication.
Researchers aimed to evaluate outcomes of H pylori treatment and identify any risk factors for failure in patients with HIV.
Vonoprazan is an oral small molecule potassium-competitive acid blocker.
Researchers investigated the effects of H pylori on the clinical presentation and disease course of COVID-19 infections.
Investigators sought to explore the past temporal trends (1988-2012) in gastric cancer incidence rates in 43 countries and to predict future trends (2012-2030).
Investigators tested the accuracy of the EndoFaster® device in performing gastric juice analysis, with the goal of reducing the need for gastric biopsies in the detection of H pylori.
Researchers compared the efficacy of 10-Day Bismuth Quadruple Therapy vs 7-day Clarithromycin Triple Therapy.
Researchers assessed the correlation between Helicobacter pylori infection and biological characteristics of early gastric cancer.
Researchers assessed the effects of different H pylori infections on distribution of histopathological characteristics and items of serum gastric function.
Investigators evaluated the relationship among Helicobacter pylori infection, atrophic gastritis, and chronic kidney disease.
A team of investigators conducted a multicenter, randomized, controlled trial to identify factors related to the eradication of H pylori with dual vonoprazan and amoxicillin as first-line therapy.
A team of investigators sought to determine factors that affect the success of second-line therapy using vonoprazan, a gastric acid secretion inhibitor that improves the success rate of Helicobacter pylori eradication.
The American Gastroenterological Association issued a clinical practice update to provide clinicians with practical advice on how to manage patients for whom initial treatment for H pylori infection was unsuccessful.
Investigators performed a cross-sectional study to assess reflux esophagitis in patients having undergone successful eradication of Helicobacter pylori infection.